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Abstract
Background: The increasing emergence of drug-resistant tuberculosis presents a threat to the effective control
of tuberculosis (TB). Rapid detection of drug-resistance is more important than ever to address this scourge. The
purpose of this study was to genotypically characterize the first-line antitubercular drug-resistant isolates collected
over 11 years in Quebec.
Results: The main mutations found in our resistant strains collection (n = 225) include: the S315T substitution in
katG (50.2 %), the -15 C/T mutation in the inhA promoter (29 %); the S531L substitution in rpoB (43 %); the deletion
8 bp 446 / + R140S in pncA (72.9 %); the M306I (35.7 %) and M306V (21.4 %) substitutions in embB. Ten of the
mutations in katG and 4 mutations identified in pncA were previously undescribed.
Conclusion: Screening of mutations conferring resistance to first-line antituberculous drugs using DNA-sequencing
approach seems to be feasible and would drastically shorten the time to determine the resistance profile compared
to the proportion method.
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Background
In Canada, TB continues to affect Canadian populations
disproportionately although the numbers of cases have
been steadily decreasing over the past 30 years [1]. Drug
resistance was found to be uncommon in Canadian-born
TB patients. The highest rates of multidrug-resistant TB
(MDR-TB) were from patients originating from the Eastern
European region, and secondly, from the Western Pacific
region. MDR-TB is defined resistance to at least isoniazid
and rifampicin, whereas extensive drug resistant TB
(XDR-TB) is an MDR-TB plus resistance to at least one
injectable second-line drug and a fluoroquinolone.
From the period of 1997 to 2008, there were 5 cases of
extensively drug-resistant TB (XDR-TB), 177 cases of
MDR-TB, and 1234 cases of first-line drug resistance
not-MDR [2]. These five XDR-TB cases were reported
in Ontario. The first XDR-TB case reported in the province
of Quebec occurred in 2013 and concerned a patient emi-
grating from Eastern Europe (H. Soualhine, pers. comm.)
With the increase in the number of cases of drug-
resistant TB steadily emerging, and more of them becom-
ing MDR or XDR-TB, a better knowledge of the molecular
mechanisms of antitubercular drug-resistance have a
significant impact on the improvement of rapid detec-
tion techniques and the diagnosis of drug resistance. In
Quebec, primary identification of M. tuberculosis complex
is based on Cobas TaqMan MTB assay (Roche Diagnostics,
Rotkreuz, Switzerland). Rapid detection of rifampin resist-
ance, based on Xpert MTB/RIF assay (Cepheid, Sunnyvale,
CA, USA), is performed on selected specimens. Confirma-
tory identification at the species level is done using a PCR-
based genomic deletion analysis of RD-regions [3] and drug
susceptibility testing (DST) is performed using the pheno-
typic MGIT 960 method (Becton Dikinson, MD, USA).
First-line antituberculous drug resistance mechanisms
are well studied. Several genes have been associated with
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drug resistance, namely katG and inhA, with isoniazid
(INH) resistance; rpoB with rifampicin (RMP) resistance;
embCAB with ethambutol (EMB) resistance; and pncA with
pyrazinamide (PZA) resistance [4–7]. Line-probe assays
(LPAs) including the (INNO-LiPA Rif.TB (Innogenetics,
Zwijndrecht, Belgium) and the GenoType MTBDRplus
(LPA), (HainLifeScience GmbH, Nehren, Germany) and
Xpert MTB/RIF (Cepheid) have been formally endorsed by
the World Health Organization and are now in routine use
in many TB laboratories [8]. The polymerase chain reaction
sequencing-based approach is an accurate and rapid
method for detection of drug-resistant TB and can
identify several mutant alleles not previously associated
with resistant organisms [4–7]. Recently, whole genome
sequencing (WGS) of M. tuberculosis offers a powerful
new approach to the identification of drug resistance.
Furthermore, WGS of pathogens is becoming part of
routine practice for establishing transmission and re-
sistance patterns [9].
The aim of this study was to genotypically characterize
resistant strains of M. tuberculosis circulating in Quebec,
and to analyze the frequency of mutations conferring
resistance to the four first-line antitubercular drugs
using a DNA-sequencing approach.
Methods
M. tuberculosis isolates (n = 2248) were obtained from
clinical specimens submitted for TB culture to the Public
Health Laboratory in Quebec. Resistant isolates were
selected based on drug resistance profiles (n = 225) to the
four first-line drugs: INH, RMP, PZA, and EMB. Suscep-
tible strains (n = 32) were included and two reference
strains were selected: M. tuberculosis H37Ra reference
strain ATCC 25177; and M. bovis BCG strain ATCC
35734 that is naturally resistant to PZA.
Drug susceptibility testing (DST)
All M. tuberculosis clinical isolates were tested for
drug susceptibility using the BACTEC 460 instrument
(Becton Dikinson, Sparks, MD, USA) from 2002 to
2005, the BACTEC MGIT 960 (Becton Dikinson) from
2010 to 2012, or by both instruments between 2006
and 2009. Critical drug concentrations used in the
BACTEC 460 were INH 0.1 μg/ml, RMP 2.0 μg/ml,
PZA 100 μg/ml, and EMB 2.0 μg/ml. For the BACTEC
MGIT 960 instrument, critical concentrations used
were INH 0.1 and 0.4 μg/ml, RMP 1.0 μg/ml, PZA
100 μg/ml, and EMB 5.0 μg/ml [10].
The drug-resistant isolates were plated on Lowenstein-
Jensen slants at 37 °C. DNA was extracted using the
BioRobot M48 (Qiagen, Hilden, Germany) [11]: Isolates
were prepared for DNA extraction by suspending rep-
resentative colonies in tubes containing beads and lysis
buffer. The samples were vortexed, heated at 100 °C for
25 min, cooled on ice for 2 min, and then put in the Mini-
Beadbeater (Biospec Products, Inc. Bartlesville, OK, USA)
for 2 min. Finally the suspensions were centrifuged at
14 000 rcf for 2 min, before being placed in the BioRobot,
and the DNA was eluted into RNase-free water.
PCR and DNA sequencing reactions
Six pairs of oligonucleotide primers were designed to
amplify regions of five genes associated with resistance
to four antituberculosis drugs. PCR primers are listed in
Table 1. DNA was amplified in a 50 μl mixture containing
PCR buffer, 200 μM dNTP, 2 mM MgCl2, 0.5 μM of each
primer, 1 unit of AmpliTaq® DNA polymerase (Applied
Biosystems, Carlsbad, CA, USA) and 5 μL of genomic
DNA. The reaction was performed as follows: 5 min at
95 °C, followed by 40 cycles of denaturation for 30 s at
95 °C, annealing for 30 s at 60 °C, and extension for 30 s
at 72 °C, with a final elongation step of 7 min at 72 °C.
The amplicons were purified using a MinElute 96 UF PCR
purification plates (MinElute, Qiagen) and added as
template for bidirectional DNA sequencing using an
ABI PRISM BigDye® terminator cycle sequencing kit v. 3.1
(Applied Biosystems, Woolston Warrington, UK). Reac-
tions mixtures containing the forward or reverse primers
were analysed with an ABI PRISM 3130xl genetic analyzer
(Applied Biosystems). Bioinformatic analysis was done
using the Lasergene (v. 10) software (DNAStar Inc.
Madison, WI, USA). The obtained sequences were aligned
in a multiple sequence alignments with the wild-type se-
quences of katG, inhA promoter, rpoB, pncA, and embB.
Table 1 Primers used for drug resistant gene amplification
Genes Primers (Sequences 5’→ 3’) Product
size (bp)
katG katG-F (5’-GACATTCGCGAGACGTTTCGG-3’) 642
katG-R (5’GCTCTTAAGGCTGGCAATCTCG-3’)
inhA inhA-F (5’-CTATATCTCCGGTGCGGTCA-3’) 469
inhA-R (5’-CTTGGCCATCGAAGCATAC-3’)
inhA-Prom inhA-Prom-1 (5’-TCCGTCATGGTCGAAGTGTG-3’) 211
inhA-Prom-2 (5’-GGTAACCAGGACTGAACGGG-3’)
rpoB rpoB-F (5’-ACGGTCGGCGAGCTGATCC-3’) 351
rpoB-R (5’-CAGACCGATGTTGGGCCCCT-3’)
pncA pncA-F1 (5’-GGCGTCATGGACCCTATATC-3’) 670
pncA-R1 (5’-CAACAGTTCATCCCGGTTC-3’)
embB embB-1 (5’- TGATATTCGGCTTCCTGCTC-3’) 417
embB-2 (5’- ACCGCTCGATCAGCACATAG-3’)
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Sensitivity and specificity were determined using the
Diagnostic Effectiveness calculation from the Simple Inter-
active Statistical Analysis (SISA) software (Hilversum, The
Netherlands) [12].
ΔkatG analysis
Three INH-resistant clinical isolates repeatedly provided
no amplication of katG gene fragment using the primer
pairs previously listed. To confirm a katG gene deletion
(ΔkatG), amplification of other regions of this gene was
investigated using different primer pairs. PCR was per-
formed as described above with a second set of primers
listed in Table 1, katGD-1 and katGD-2, designed to amp-
lify a 590 bp fragment upstream from that amplified with
the katG primers initially used. In addition, katGD-5 and
katGD-6 were used to amplify a 400 bp region of the katG
gene that overlaps with the region targeted by the katG-F
and katG-R primers.
Catalase-peroxidase assays
A semi-quantitative catalase assay was performed in dupli-
cate as previously described [13], on three ΔkatG strains
and five selected INH-resistant strains with undescribed
katG gene mutations. Controls included the reference
strains of M. tuberculosis, M. avium ATCC 700898 for
low catalase activity, and M. gordonae ATCC35756 for
high catalase activity.
Results
The province of Quebec has reported a total of 2248
strains of M. tuberculosis between 2002 and 2012, of
which 225 were resistant (Fig. 1). Drug resistant TB in
Quebec is mainly associated with INH and PZA mono-
resistance. Among the 225 phenotypically resistant isolates
selected, 20 were MDR-TB. Mono-resistance patterns
include 155 to INH, 3 to RMP and 41 to PZA. Six isolates
were resistant to at least two first-line drugs but were not
MDR. In total, 180 isolates were resistant to INH, 23 to
RMP, 48 to PZA, and 14 isolates were resistant to EMB.
katG gene
Out of 180 phenotypically INH-resistant isolates, 110
had a mutation in the targeted region of katG (61 %)
(Table 2) and 3 isolates were ΔkatG.
A total of 10 mutations in katG gene were novel and
found in INH monoresistant strains; five undescribed
substitutions occurred alone (V284G; P375R; Y413C; del
G1284 and D448N) and five substitutions occurred in
combination with a mutation known to confer INH-
resistance, among them P280S and S303A occurred
with -15 C/T in inhA promoter while D387H; V450S;
and G451S occurred with S315T in katG. The main
mutation in katG (50.2 %) was the AGC/ACC (S315T). In
8.8 % of the S315T mutants, inhA promoter mutations
were also identified. Three INH-resistant isolates demon-
strated no amplification of the katG gene fragment using
the primer pairs katG-F/katG-R, katGD-1/katGD-2 and
katGD-5/katGD-6. No catalase activity was observed by
the semi-quantitative catalase assay on those three clinical
isolates compared to the control strains of M. tuberculosis,
the weak catalase producer M. avium and the strong pro-
ducer, M. gordonae, which showed an average of 28 mm,
9 mm and 57 mm of oxygen bubble production respect-
ively. The katG mutated strains (V284G; P375R; Y413C;
Fig. 1 Annual profile of resistant TB in Quebec 2002-2012
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Table 2 INH-Resistance conferring mutations in 180 INH-R (85 %) and 32 INH-S (15 %) isolates
Drug resistance Genes No. of isolates Changes







katG 1 CCG/CGG P375Ra
1 TAC/TGC Y413Ca




1 AGC/ACC, TGA/TAA S315T, 343Stop
1 AGC/ACC, GAT/CAT S315T, D387Hb
1 AGC/ACC, GTC/GAC S315T, V450Db
1 AGC/ACC, GGC/AGC S315T, G451Sb
Single mutations
inhA 3 TCG/GCG S94A
1 -8 T/C None
inhA-p 37 -15C/T None
3 -17G/T None
Multiple mutations
inhA-p 1 -15C/T, -47 G/T None
inhA, inhA-p 1 GGA/GGC, -15C/T G3G, None
2 ATC/ACC, -15C/T I21T, None
3 ATC/GTC, -15C/T I21V, None
katG, inhA 1 AGC/ACC, GGA/GGC S315T, G3G
3 GAA/GAC, -15C/T E261D, None
katG, inhA-p 1 CCG/TCG, -15C/T P280Sb, None
1 TCG/GCG, -15C/T S303Ab, None
1 ACC/GCC, -15C/T T314A, None
1 AGC/AAC, -47G/C S315N, None
2 AGC/ACC, -8 T/A S315T, None
3 AGC/ACC, -8 T/C S315T, None
2 AGC/AAC, -15C/T S315T, None
1 AGC/AAC, -102G/A S315T, None
1 ACT/ATT, -15C/T T308I, None
katG, inhA, inhA-p 19 WT None
INHS katG, inhA, inhA-p 32 WT None
aUndescribed mutations that occur alone; bundescribed mutations that occur in combination with another resistance-associated mutation; inhA-p, inhA promoter,
del, deletion; WT wild-type sequence, R resistant, S susceptible
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del G1284 and D448N) identified in our study, have
shown a catalase activity of 19 mm, 21 mm, 38 mm,
11 mm and 27 mm respectively.
inhA gene
Eight out of the 180 INH-resistant isolates (4.4 %) con-
tained a single point mutation in the inhA gene. Three iso-
lates had an I21V substitution, 2 had an I21T substitution,
and 3 had a S94A substitution. The substitutions at codon
21 always occurred in combination with the -15 C/T
mutation in the inhA promoter.
inhA promoter
Isolates with a mutation in the inhA promoter made up
a total of 36 % of INH-resistances. The most commonly
encountered mutation was -15 C/T (29 %), followed by
mutations at position -8 (3.9 %). The mutations at -47
and -102 always occurred in combination with the -15
C/T inhA-promoter mutation, the S315T, or the S315N
substitution in katG, which are mutations known to
confer INH-resistance.
rpoB
All RMP-resistant isolates contained a mutation in the
targeted region of the rpoB gene (Table 3): One had an
insertion of F514 (TTC), 18 had a single point mutation,
and 4 contained two point mutations. All mutations
occurred within the RMP resistance determining region
(RRDR) except T480I (ACC/ATG); this mutation oc-
curred in combination with the S531L substitution. The
most common mutation observed in rpoB was at codon
531, such as the S351L substitution, which was found in
47.8 % of the isolates. Substitutions at codon 526 were
found in 26 % of isolates. Two L511R substitutions
occurred in combination with D516Y.
pncA
Forty-five out of 48 PZA-resistant isolates had a mutation
in the pncA gene or in the pncA promoter (93.7 %). As
shown in Table 3, 35 PZA-monoresistant isolates had a
mutation, identified only in Quebec, which consist of a
deletion of 8 bp at position 446 (frameshift) in combin-
ation with the R140S substitution (CGC/AGC). Two
PZA-resistant strains harboured no mutation in the
pncA gene and one PZA-resistant strain contained only
a silent mutation, A46A (GCA/GCG).
embB
Thirteen of 14 EMB-resistant isolates had a mutation in
the embB gene (92.8 %). The most commonly found sub-
stitution occurred at codon 306 (57 %). Other substitutions
include Y319S, D328Y, D354A, G406S, and E378A. The
isolate with the E378A substitution also had a substitution
in codon 306 and a silent mutation in codon 355.
Mutations and MDR-TB
Twenty isolates were MDR-TB as defined by resistance to
both INH and RMP. The most common mutation com-
bination seen in the MDR-TB isolates was in rpoB531 and
katG315 (40 %), followed by rpoB526 and katG315 (15 %),
and inhA promoter -15 with rpoB531 (15 %) among others
(Table 4).
Discussion
Phenotypic DST is performed using the BACTEC MGIT
960 system. While this method is termed the gold standard
for determining drug susceptibility profiles of M. tuber-
culosis isolates, it can take two weeks before results are
available. Limitations of phenotypic methods include the
uncertain reliability of conventional breakpoints, decreased
accuracy in cultures mixed with other mycobacteria, and
the possibility of reduced fitness and growth of mutant or-
ganisms, which may require a higher inoculum to increase
test sensitivity. Further, DST to PZA can be hampered by
false-positive results [14].
In our study, DNA sequencing is applicable for the de-
tection of INH-resistant isolates with 60.8 % sensitivity
(95 % CI, 51.7 to 69.8) and 100 % specificity for the katG
gene and with 35.9 % sensitivity (95 % CI, 27 to 44.8)
and 100 % specificity for the inhA promoter. Combined
the two tests have 85.1 % sensitivity (95 % CI, 78.5 to
91.7) and 100 % specificity.
Ten mutations identified in the katG gene of the INH-
resistant isolates were undescribed according to our
knowledge. Five substitutions occurred in combination
with resistance-associated mutations, meaning that the
resistance observed with these isolates can be attributed
to the well-established resistance-conferring mutations;
these undescribed mutations could also be associated
with fitness cost of INH resistance [15]. The remaining
five undescribed substitutions that occurred alone (V284G,
P375R, Y413C, del G 1284, and D448N) require further
analysis. Five strains harboring these mutations showed
catalase activity. Among them, 3 strains (V284G, P375R,
and del G 1284) showed a reduced catalase activity com-
pared to the control strains.
In our isolates, the S315T substitution accounted for
50.2 % of the katG gene mutations. This particular substitu-
tion has also been reported to occur more frequently in
MDR-TB isolates, presumably because it provides INH re-
sistance with the retention of virulence [16]. This would
allow the S315T mutated strains to persist in the intracellu-
lar environment and possibly become resistant to additional
antitubercular drugs. In three strains of our collection, the
deletion of katG resulted in no KatG enzymatic activity,
and therefore, INH cannot be converted into its active
form. It was shown that when KatG activity has been
completely lost, ahpC promoter mutations are usually
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Table 3 Characteristic of mutations found in resistant isolates to RMP (n = 23), PZA (n = 48) or EMB (n = 14) compared to susceptible
strains (n = 32)
Drug resistance Genes No. of isolates Changes
RMPR rpoB 23 Nucleotides Amino acid
Single mutations








2 CTG/CGG, GAC/TAC L511R, D516Y
2 TCG/TTG, ACC/ATG S531L, T480I





1 Del G164 Frameshifta
2 ATC/AGC I90S
1 GCG/CCG A92Pa
1 Del 9 bp 380 Del D,E,Va
1 ACC/CCC T135P
1 Ins AT 447 Frameshifta
1 ACC/CCC T168P
Multiple mutations
35 Del8 bp446, CGC/AGC Frameshift, R140S
1 GCA/GCG A46A
2 WT None










1 ATG/ATA, CTG/CTA, GAG/GCG M306I, L355L, E387A
1 WT None
EMBS embB 32 WT None
aUndescribed mutations; Del deletion, Ins insertion, WT wild-type sequence, R resistant, S susceptible
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found. The ahpC gene encodes an enzyme involved in
antioxidant defense, as does the katG gene product [13].
inhA promoter mutations made up 36 % of the INH-
resistant isolates. Two rarely reported mutations were
also identified at positions -47 and -102. As these two
mutations always occur in combination with the S315T
substitution in katG as previously found, their conse-
quences are unknown at the present time.
In contrast, there were 19 INH-resistant isolates that
did not have any mutations in katG, inhA, or the inhA
promoter; other mechanisms of resistance could be at
play. Mutations in other genes such as ahpC, kasA,
ndh,and mshA have also been reported [17], in addition
to efflux-related mechanisms [18, 19].
We have identified rpoB mutations in 100 % of the
RMP-resistant isolates. Previous studies indicate that
mutations at codons 531, 526, and 516 make up the major-
ity of RMP-resistance mutations reported [20]. All muta-
tions identified in the rpoB gene occurred within the RRDR
except one substitution, T480I, which occurred outside of
this core region. Both isolates that had the T480I substitu-
tion also had S531L substitution; it is unclear whether the
T480I substitution is involved in RMP resistance [21]. One
insertion of F514 was identified in our collection. This in-
sertion was also reported in a strain isolated from the same
patient in Ontario [22].
RMP mono-resistance is rarely reported [20]. In this
study 87 % of the RMP-resistant isolates were also resistant
to INH, making them MDR-TB. The molecular tests could
therefore be used to identify the majority of MDR-TB cases.
The automated PCR test utilizing the GeneXpert platform,
which can accurately detect TB as well as RMP resistance
within 2 h, is useful for detecting MDR-TB [8]. As with the
line probe assay, not all mutations will be identified in the
rpoB gene that confers RMP resistance. Novel mutations
cannot be identified, and other mutations cannot be de-
tected with these assays [23–25].
Mutations in the pncA gene and promoter accounted
for 93.8 % of PZA resistance. DNA sequencing had de-
tected PZA resistance with a sensitivity of 93.8 % (95 %
CI, 85 to 100) and specificity of 100 %. Among the
Canadian-born population in Quebec, a high proportion
of TB isolates are monopyrazinamide-resistant comparing
to the other provinces [2, 26]. In the absence of a rec-
ognized outbreak, it was hypothesized that these iso-
lates most likely represented reactivation of an old
endemic strain [26]. The most common mutation seen
in the province was a deletion of 8 bp at position 446
combined with a R140S substitution (72.9 %). Previous
studies have shown that strains carrying this mutation
are related [26, 27] and suggested that the clonal PZA-
resistant strains carrying this mutation are actively being
transmitted, rather than acquired resistance individually in
the patient via the selective pressures of drug exposure [26].
Four novel mutations found in our collection consisted
of a deletion (G at position 164) in INH and PZA-resistant
strain; an insertion (AT at position 447) and a deletion of
residues D, E, and V at position 380 found in 2 MDR
Table 4 Characteristic of mutations found in 20 MDR isolates
No. of MDR isolates RMP INH EMB PZA
rpoB katG inhA inhA-p embB pncA
1 L511R, D516Y S315T
1 L511R, D516Y S315T del 9 bp 380 (del D,E,V)
1 Ins F514 S315T T-8A T168P
1 D516V S315T T-8A G406S InsAT 447
1 D516V E261D C-15 T
1 H526D S315T
1 H526D S315T M306I
1 H526D S315T D328Y
1 S531F S315T
2 S531L S315T
1 S531L S315T C-15 T Y319S
2 S531L C-15 T
1 S531L I21T C-15 T M306I
1 S531L S315T D354A T135P
1 S531L S315T T-8C A-11G
2 S531L, T480I S315T M306V
1 L533P S315T M306I L27P
inhA-p inhA promoter, del deletion, Ins insertion
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strains, and the A92P substitution in one monoresistant
strain. There were 3 PZA-resistant isolates that did not
have a mutation in the pncA gene; this cannot rule out a
false resistant result by the phenotypic method [14]. Fur-
thermore, not all PZA-resistant M. tuberculosis isolates
have mutations in this gene [28], which is suggestive of
other mechanisms of resistance. For instance, mutations in
the rpsA gene, encoding ribosomal protein S1, have been
described as a mechanism for PZA resistance. A silent
mutation of A46A was identified in one isolate. According
to Somoskovi et al., this SNP is reported to serve as a
marker of M. canettii, which is naturally resistant to PZA,
but not as a result of pncA mutations [29]. This strain,
which was probably misidentified as M. tuberculosis, since
it also contains the RD9 region, showed smooth col-
onies, characteristic of M. canettii [3]. Other mechanisms
reported to cause PZA resistance in M. tuberculosis, M.
canettii, and M. bovis include: altered PZA uptake and/or
pyrazinoic acid efflux [30].
EMB-resistance conferring mutations were identified
in 13 out of 14 EMB-resistant isolates (sensitivity of 92.8 %
(95 % CI, 75.6 to 100) and a specificity of 100 %). Fifty-
seven percent of identified substitutions occurred at
codon 306 which is the most common site reported for
changes associated with EMB resistance [31]. A substi-
tution, E378A, was found in one EMB-resistant clinical
isolate in our collection. The same mutation was also
identified in one EMB-susceptible clinical isolate, and in
the EMB-susceptible control, M. bovis BCG TMC1011 as
was previously reported upon whole genome sequencing
[32]. Our EMB-resistant isolate also contained the M306I
substitution. The substitution caused by E378A in the
BCG and clinical isolate are not associated with EMB-
resistance, and are reported as polymorphism that is not
resistance related.
One EMB-resistant isolate did not have mutations in
the embB gene, which may indicate other mechanisms of
EMB resistance do exist [33]. An efflux pump mechanism
has been associated with resistance to EMB [18], and oc-
casionally resistance-conferring mutations have also been
reported in embC [34].
Conclusion
DNA sequencing was able to detect mutations in the
targeted genes: katG (62 %); inhA promoter (36 %); inhA
gene (4.4 %); katG and inhA promoter together (89.5 %).
From RMP, PZA, and EMB, 100 %, 93.7 %, and 92.8 %
of resistant strains showed a mutation in rpoB, pncA,
and embB, respectively. Comparing to the phenotypic
methd, DNA sequencing of targeting genomic regions
associated with drug resistance would drastically shorten
time to resistance profile determination in clinical iso-
lates collected in the region.
It is of great importance to note that the absence of a
mutation does not imply drug susceptibility; therefore, it
is essential that molecular methods must always be
compared to the gold standard method.
Abbreviations
CI, Confidence Interval; DST, drug susceptibility testing; EMB, ethambutol; INH,
isoniazid; MDR-TB, multidrug-resistant tuberculosis; PZA, pyrazinamide; RMP,
rifampin; RRDR, rifampin resistance determining region; SISA, simple interactive
statistical analysis; XDR-TB, extensively drug-resistant tuberculosis; ΔkatG,
katG gene deletion.
Acknowledgments
The authors would like to thank Florence Doualla-Bell, for reviewing this paper;
Isabelle Noel, Lise Côté and Marc-Christian Domingo for their technical assistance.
Funding
This work was supported by the Institut national de santé publique du
Quebec – LSPQ- Sainte-Anne-de-Bellevue, Quebec, Canada.
Availability of data and materials
Data supporting our findings are contained within the manuscript and can
be shared.
Authors’ contributions
JS and HS participated in the design, data collection, and analysis and
manuscript development. JS, EB, EBT and HF participated in technical work,
data analysis, and interpretation of the data. CT, JS and HS participated in
interpretation of the data, reviewed the manuscript. All authors read and
approved the final manuscript.
Authors’ information
Joanna Spinato completed this work at the LSPQ as M.Sc. student in the
Institute of Parasitology at McGill University (Montreal, Quebec). She is
currently the Occupational Health and Safety Officer at the Public Health
Ontario Laboratory in Toronto, ON, Canada.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The M. tuberculosis isolates were selected from the bacterial collection maintained
at the mycobacteriology laboratory at the Laboratoire de santé publique du
Quebec. The study was approved by the Institut national de santé publique du
Quebec Research Ethical Committee - Sainte-Anne-de-Bellevue, Quebec, Canada.
Author details
1McGill University, Montreal, Quebec, Canada. 2Laboratoire de santé publique
du Quebec, 20045 chemin Sainte-Marie, Sainte-Anne de Bellevue, Quebec
H9X 3R5, Canada. 3Université de Montreal, Montreal, Quebec, Canada.
4Present address: Public Health Ontario Laboratory, Toronto, Ontario M5G
1 M1, Canada.
Received: 1 February 2016 Accepted: 22 July 2016
References
1. Public Health Agency of Canada. The Chief Public Health Officer’s Report on
the State of Public Health in Canada, 2013. Infectious Disease - The Never-
ending Threat. 2013. http://www.phac-aspc.gc.ca/cphorsphc-respcacsp/
2013/tuber-eng.php. Accessed 16 Dec 2013.
2. Minion J, Gallant V, Wolfe J, Jamieson F, Long R. Multidrug and extensively
drug-resistant tuberculosis in Canada 1997–2008: Demographic and disease
characteristics. PLoS One. 2013;8(1):e53466. doi:10.1371/journal.pone.0053466.
3. Mostowy S, Cousins D, Brinkman J, Aranaz A, Behr MA. Genomic deletions
suggest a phylogeny for the Mycobacterium tuberculosis complex. J Infect
Dis. 2002;186(1):74–80.
Spinato et al. BMC Microbiology  (2016) 16:164 Page 8 of 9
4. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and
isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591–3.
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T,
Collins D, de Lisle G, Jacobs Jr WR. inhA, a gene encoding a target for isoniazid
and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227–30.
6. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L,
Schopfer K, Bodmer T. Detection of rifampicin-resistance mutations in
Mycobacterium tuberculosis. Lancet. 1993;341:647–50.
7. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. Mutations associated
with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex
organisms. Antimicrob Agents Chemother. 1997;41(3):636–40.
8. World Health Organization (WHO). Automated real-time nucleic acid
amplification technology for rapid and simultaneous detection of tuberculosis
and rifampin resistance: Xpert MTB/RIF System Policy Statement. Geneva,
Switzerland. 2011: http://apps.who.int/iris/handle/10665/112472 Accessed 22 July
2016.
9. Williams OM, Abeel T, Casali N, Cohen k, Pym AS, Mungall SB, Desjardins CA,
Banerjee A, Drobniewski F, Earl AM, Graham S., Cooke GS. Fatal nosocomial
MDR TB identified through routine genetic analysis and whole-genome
sequencing. Emerg Infect Dis. 2015; doi:10.3201/eid2106.141903.
10. Becton Dickinson and Company. BD BACTEC MGIT 960 SIRE Kits for the
antimycobacterial susceptiblity testing of Mycobacterium tuberculosis.
Sparks: BD; 2015 (Publication number 8008200(02)) http://www.bd.com/
ds/technicalCenter/inserts/8008200(02).pdf#page=1&view=Fit. Accessed
21 July 2016.
11. Qiagen. MagAttract DNA Mini M48 Handbook. Hilden: Qiagen; 2012.
12. Uitenbroek DC. SISA-Binomial. 1997. http://www.quantitativeskills.com/sisa/
distributions/binomial.htm. Accessed 5 Dec 2013.
13. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T,
Graviss EA. Single nucleotide polymorphisms in genes associated with
isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents
Chemother. 2003;47(4):1241–50.
14. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for
erroneous results indicating resistance when using the Bactec MGIT 960
system for testing susceptibility of Mycobacterium tuberculosis to
pyrazinamide. J Clin Microbiol. 2010;48(1):300–1.
15. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-
resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(12):1456–66.
16. Hazbón MH, Brimacombe M, del Valle MB, Cavatore M, Guerrero MI, Varma-
Basil M, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, León CI, Bose
M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce
de León A, Alland D. Population genetics study of isoniazid resistance
mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2006;50:2640–9.
17. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug
resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol. 2006;8(2):97–111.
18. Colangeli R, Helb D, Sridharan S, Sun J, Varma Basil M, Hazbón MH,
Harbacheuski R, Megjugorac NJ, Jacobs Jr WR, Holzenburg A, Sacchettini JC,
Alland D. The Mycobacterium tuberculosis iniA gene is essential for activity of
an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Mol Microbiol. 2005;55:1829–40.
19. Jiang X, Zhang W, Zhang Y, Gao F, Lu C, Zhang X, Wang H. Assessment of
efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis
by real-time reverse transcription PCR. Microb Drug Resist. 2008;14:7–11.
20. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin
monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob
Agents Chemother. 2013;57:893–900.
21. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP.
Contribution of rpoB mutations to development of rifamycin cross-resistance in
Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42(7):1853–7.
22. Bolotin S, Alexander DC, Chedore P, Drews SJ, Jamieson F. Molecular
characterization of drug-resistant Mycobacterium tuberculosis isolates from
Ontario, Canada. J Antimicrobial Chemother. 2009;64:263–6.
23. Perdigão J, Macedo R, João I, Fernandes E, Brum L, Portugal I. Multidrug-resistant
tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb
Drug Resist. 2008;14(2):133–43.
24. Kalokhe AS, Shafiq M, Lee JC, Metchock B, Posey JE, Ray SM, Anderson A,
Wang YF, Nguyen ML. Discordance in Mycobacterium tuberculosis rifampin
susceptibility. Emerg Infect Dis. 2012;18:537.
25. McAlister AJ, Driscoll J, Metchock B. DNA sequencing for confirmation of
rifampin resistance detected by Cepheid Xpert MTB/RIF assay. J Clin Microbiol.
2015;53(5):1752–3.
26. Nguyen D, Brassard P, Westley J, Thibert L, Proulx M, Henry K, Schwartzman K,
Menzies D, Behr MA. Widespread pyrazinamide-resistant Mycobacterium
tuberculosis family in a low-incidence setting. J Clin Microbiol. 2003;41:2878–83.
27. Cheng S, Thibert L, Sanchez T, Heifets L, Zhang Y. pncA mutations as a major
mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread
of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother.
2000;44:528–32.
28. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ,
van Soolingen D. Validation of pncA gene sequencing in combination with the
mycobacterial growth indicator tube method to test susceptibility of
Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2012;50:428–34.
29. Somoskovi A, Dormandy J, Parsons LM, Kaswa M, Goh KS, Rastogi N, Salfinger M.
Sequencing of the pncA gene in members of the Mycobacterium tuberculosis
complex has important diagnostic applications: identification of a species-specific
pncA mutation in “Mycobacterium canettii” and the reliable and rapid predictor of
pyrazinamide resistance. J Clin Microbiol. 2007;45:595–9.
30. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of
pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to
pyrazinamide. J Bacteriol. 1999;181(7):2044–9.
31. Plinke C, Rüsch-Gerdes S, Niemann S. Significance of mutations in embB
codon 306 for prediction of ethambutol resistance in clinical Mycobacterium
tuberculosis isolates. Antimicrob Agents Chemother. 2006;50:1900–2.
32. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopeć E, Zwolska Z, Kirikae
F, Toyota E, Kobayashi I, Morita K, Kudo K, Kato S, Kuratsuji T, Mori T, Kirikae
T. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin
Microbiol. 2007;45:179–92.
33. Alcaide F, Pfyffer GE, Telenti A. Role of embB in natural and acquired resistance to
ethambutol in mycobacteria. Antimicrob Agents Chemother. 1997;41:2270–3.
34. Plinke C, Cox HS, Zarkua N, Karimovich HA, Braker K, Diel R, Rüsch-
Gerdes S, Feuerriegel S, Niemann S. embCAB sequence variation among
ethambutol-resistant Mycobacterium tuberculosis isolates without
embB306 mutation. J Antimicrob Chemother. 2010;65:1359–67.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Spinato et al. BMC Microbiology  (2016) 16:164 Page 9 of 9
